Do analysts recommend NNVC or PLYX?

Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 255.87%. Given Polaryx Therapeutics' higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better valuation & earnings, NNVC or PLYX?

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A Polaryx Therapeutics N/A N/A N/A -$0.05 N/A

Is NNVC or PLYX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Polaryx Therapeutics N/A N/A N/A

Do analysts rate NNVC or ALDX?

Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 142.29%. Given Aldeyra Therapeutics' higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation & earnings, NNVC or ALDX?

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A

Is NNVC or ALDX more profitable?

Aldeyra Therapeutics' return on equity of -57.34% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% Aldeyra Therapeutics N/A -57.34% -36.33%

Do analysts recommend PEPG or NNVC?

PepGen currently has a consensus price target of $11.50, indicating a potential upside of 553.41%. Given PepGen's higher possible upside, equities analysts plainly believe PepGen is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, PEPG or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PepGen N/A N/A -$89.65M -$1.75 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is PEPG or NNVC more profitable?

PepGen's return on equity of -59.89% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets PepGen N/A -59.89% -49.62% NanoViricides N/A -87.90% -78.69%

Does the media prefer PEPG or NNVC?

In the previous week, PepGen and PepGen both had 1 articles in the media. PepGen's average media sentiment score of 0.94 beat NanoViricides' score of 0.25 indicating that PepGen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PepGen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate LIXT or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has better earnings & valuation, LIXT or NNVC?

Lixte Biotechnology is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lixte Biotechnology N/A N/A -$6.01M -$1.13 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is LIXT or NNVC more profitable?

NanoViricides' return on equity of -87.90% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% NanoViricides N/A -87.90% -78.69%

Does the media prefer LIXT or NNVC?

In the previous week, Lixte Biotechnology had 2 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Lixte Biotechnology and 1 mentions for NanoViricides. Lixte Biotechnology's average media sentiment score of 0.63 beat NanoViricides' score of 0.25 indicating that Lixte Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lixte Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NNVC or ENGN?

enGene has a consensus price target of $11.05, indicating a potential upside of 520.53%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than NanoViricides. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 enGene 2 Sell rating(s) 8 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.14

Which has stronger valuation & earnings, NNVC or ENGN?

NanoViricides is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NanoViricides N/A N/A -$8.29M -$0.43 N/A enGene N/A N/A -$117.30M -$2.17 N/A

Is NNVC or ENGN more profitable?

enGene's return on equity of -56.06% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NanoViricides N/A -87.90% -78.69% enGene N/A -56.06% -45.64%

Does the media refer more to NNVC or ENGN?

In the previous week, enGene had 12 more articles in the media than NanoViricides. MarketBeat recorded 13 mentions for enGene and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.25 beat enGene's score of 0.22 indicating that NanoViricides is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

NanoViricides (NNVC) Competitors

$1.33 -0.02 (-1.48%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.35 +0.02 (+1.80%)

As of 07/2/2026 07:59 PM Eastern

Compare

NNVC vs. PLYX, ALDX, PEPG, LIXT, and ENGN

Should you buy NanoViricides stock or one of its competitors? MarketBeat compares NanoViricides with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NanoViricides include Polaryx Therapeutics (PLYX), Aldeyra Therapeutics (ALDX), PepGen (PEPG), Lixte Biotechnology (LIXT), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.

How does NanoViricides compare to Polaryx Therapeutics?

NanoViricides (NYSE:NNVC) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Polaryx Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Polaryx Therapeutics	N/A	N/A	N/A

In the previous week, NanoViricides had 1 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.89 beat NanoViricides' score of 0.25 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NanoViricides	Neutral
Polaryx Therapeutics	Very Positive

10.3% of NanoViricides shares are owned by institutional investors. 3.6% of NanoViricides shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Polaryx Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Polaryx Therapeutics	N/A	N/A	N/A	-$0.05	N/A

Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 255.87%. Given Polaryx Therapeutics' higher probable upside, analysts clearly believe Polaryx Therapeutics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NanoViricides and Polaryx Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does NanoViricides compare to Aldeyra Therapeutics?

NanoViricides (NYSE:NNVC) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 3.6% of NanoViricides shares are held by insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A

Aldeyra Therapeutics has a consensus target price of $5.50, indicating a potential upside of 142.29%. Given Aldeyra Therapeutics' higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aldeyra Therapeutics' return on equity of -57.34% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Aldeyra Therapeutics	N/A	-57.34%	-36.33%

NanoViricides has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

In the previous week, NanoViricides had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 1 mentions for NanoViricides and 0 mentions for Aldeyra Therapeutics. NanoViricides' average media sentiment score of 0.25 beat Aldeyra Therapeutics' score of 0.00 indicating that NanoViricides is being referred to more favorably in the media.

Company	Overall Sentiment
NanoViricides	Neutral
Aldeyra Therapeutics	Neutral

Summary

NanoViricides beats Aldeyra Therapeutics on 7 of the 12 factors compared between the two stocks.

How does NanoViricides compare to PepGen?

PepGen (NASDAQ:PEPG) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

PepGen has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, indicating that its stock price is 66% more volatile than the broader market.

NanoViricides is trading at a lower price-to-earnings ratio than PepGen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

PepGen's return on equity of -59.89% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PepGen	N/A	-59.89%	-49.62%
NanoViricides	N/A	-87.90%	-78.69%

In the previous week, PepGen and PepGen both had 1 articles in the media. PepGen's average media sentiment score of 0.94 beat NanoViricides' score of 0.25 indicating that PepGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PepGen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.0% of PepGen shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 1.3% of PepGen shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PepGen currently has a consensus price target of $11.50, indicating a potential upside of 553.41%. Given PepGen's higher possible upside, equities analysts plainly believe PepGen is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

PepGen beats NanoViricides on 8 of the 12 factors compared between the two stocks.

How does NanoViricides compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Lixte Biotechnology is trading at a lower price-to-earnings ratio than NanoViricides, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Lixte Biotechnology has a beta of 1.23, suggesting that its stock price is 23% more volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Lixte Biotechnology had 2 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Lixte Biotechnology and 1 mentions for NanoViricides. Lixte Biotechnology's average media sentiment score of 0.63 beat NanoViricides' score of 0.25 indicating that Lixte Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lixte Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NanoViricides' return on equity of -87.90% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
NanoViricides	N/A	-87.90%	-78.69%

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 3.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

NanoViricides beats Lixte Biotechnology on 8 of the 12 factors compared between the two stocks.

How does NanoViricides compare to enGene?

NanoViricides (NYSE:NNVC) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

In the previous week, enGene had 12 more articles in the media than NanoViricides. MarketBeat recorded 13 mentions for enGene and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.25 beat enGene's score of 0.22 indicating that NanoViricides is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

NanoViricides has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, suggesting that its share price is 128% less volatile than the broader market.

NanoViricides is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

enGene's return on equity of -56.06% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
enGene	N/A	-56.06%	-45.64%

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 10.5% of enGene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

enGene has a consensus price target of $11.05, indicating a potential upside of 520.53%. Given enGene's higher probable upside, analysts clearly believe enGene is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

enGene beats NanoViricides on 8 of the 13 factors compared between the two stocks.

Get NanoViricides News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNVC vs. The Competition

Export

Metric	NanoViricides	Pharmaceutical Industry	Medical Sector	NYSE Exchange
Market Cap	$30.57M	$987.23M	$6.82B	$23.32B
Dividend Yield	N/A	4.84%	2.68%	4.00%
P/E Ratio	-1.85	1.58	27.66	31.51
Price / Sales	N/A	115.79	532.53	16.69
Price / Cash	N/A	20.06	48.59	25.23
Price / Book	2.02	8.17	11.07	4.81
Net Income	-$8.29M	-$3.96M	$3.57B	$1.07B
7 Day Performance	-0.75%	2.96%	2.23%	0.56%
1 Month Performance	-11.92%	3.29%	4.60%	3.95%
1 Year Performance	-5.00%	51.47%	33.47%	18.30%

NanoViricides Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNVC NanoViricides	0.3032 of 5 stars	$1.33 -1.5%	N/A	-4.3%	$30.57M	N/A	N/A	20
PLYX Polaryx Therapeutics	2.8995 of 5 stars	$2.66 +5.1%	$10.00 +275.9%	N/A	$125.10M	N/A	N/A	11	Positive News Analyst Upgrade Gap Up
ALDX Aldeyra Therapeutics	3.668 of 5 stars	$2.13 +3.9%	$5.50 +158.2%	-43.3%	$123.66M	N/A	N/A	10
PEPG PepGen	3.3651 of 5 stars	$1.80 +1.1%	$11.50 +538.9%	+45.5%	$123.12M	N/A	N/A	30
LIXT Lixte Biotechnology	0.5562 of 5 stars	$7.42 -7.7%	N/A	+256.9%	$120.76M	N/A	N/A	4	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NNVC) was last updated on 7/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NanoViricides (NNVC) Competitors

NNVC vs. PLYX, ALDX, PEPG, LIXT, and ENGN

How does NanoViricides compare to Polaryx Therapeutics?

Summary

How does NanoViricides compare to Aldeyra Therapeutics?

Summary

How does NanoViricides compare to PepGen?

Summary

How does NanoViricides compare to Lixte Biotechnology?

Summary

How does NanoViricides compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NanoViricides (NNVC) Competitors

NNVC vs. PLYX, ALDX, PEPG, LIXT, and ENGN

How does NanoViricides compare to Polaryx Therapeutics?

Is NNVC or PLYX more profitable?

Does the media favor NNVC or PLYX?

Do insiders and institutionals believe in NNVC or PLYX?

Which has better valuation & earnings, NNVC or PLYX?

Do analysts recommend NNVC or PLYX?

Summary

How does NanoViricides compare to Aldeyra Therapeutics?

Do institutionals and insiders believe in NNVC or ALDX?

Which has higher valuation & earnings, NNVC or ALDX?

Do analysts rate NNVC or ALDX?

Is NNVC or ALDX more profitable?

Which has more risk and volatility, NNVC or ALDX?

Does the media refer more to NNVC or ALDX?

Summary

How does NanoViricides compare to PepGen?

Which has more risk and volatility, PEPG or NNVC?

Which has higher valuation & earnings, PEPG or NNVC?

Is PEPG or NNVC more profitable?

Does the media prefer PEPG or NNVC?

Do insiders and institutionals believe in PEPG or NNVC?

Do analysts recommend PEPG or NNVC?

Summary

How does NanoViricides compare to Lixte Biotechnology?

Which has better earnings & valuation, LIXT or NNVC?

Which has more volatility & risk, LIXT or NNVC?

Do analysts rate LIXT or NNVC?

Does the media prefer LIXT or NNVC?

Is LIXT or NNVC more profitable?

Do institutionals & insiders hold more shares of LIXT or NNVC?

Summary

How does NanoViricides compare to enGene?

Does the media refer more to NNVC or ENGN?

Which has more volatility and risk, NNVC or ENGN?

Which has stronger valuation & earnings, NNVC or ENGN?

Is NNVC or ENGN more profitable?

Do insiders & institutionals hold more shares of NNVC or ENGN?

Do analysts prefer NNVC or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNVC vs. The Competition

NanoViricides Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools